Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Thursday 19 March, 2009

Lipoxen PLC

Lipoxen enters into agreement

RNS Number : 1025P
Lipoxen PLC
19 March 2009

Lipoxen PLC

('Lipoxen' or 'the Company')

Lipoxen enters into agreement with Glide Pharma 

Collaboration to investigate delivery of SuliXen, Lipoxen's long-acting insulin candidate for Type 1 and Type 2 diabetes, using the Glide Solid Dose Injector technology

London, UK, 19 March 2009 - Lipoxen PLC (AIM:LPX), a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and siRNA delivery, announces today that it has entered into an agreement with Glide Pharma, a specialty pharmaceutical company developing products based on its proprietary needle-free drug delivery technology, the Glide SDI[TM]. The agreement is to investigate the delivery of Lipoxen's long-acting proprietary insulin, SuliXen, which is a conjugate of insulin with polysialic acid, using the Glide SDI. 

SuliXen has already shown to be safe and well tolerated in a Phase I study and the long-acting formulation of SuliXen makes this approach very attractive for the administration of insulin. This needle-free injection could also be a key competitive advantage for SuliXen as it would meet the clear demand from patients and physicians for improved forms of insulin, which have, in particular, more patient convenience.

Under the terms of the agreement Lipoxen will provide Glide Pharma with SuliXen which Glide Pharma will then incorporate into its proprietary Glide SDI, needle-free, drug delivery technology which offers the prospect of a safe, patient friendly, solution for the administration of drugs and vaccines. Financial details were not disclosed.

M. Scott Maguire, CEO of Lipoxen, said:

'We are delighted to be able to announce this collaboration with Glide Pharma. SuliXen's reduced dosing regime already suggests it has the potential to become a recognised competitor in the $12 billion insulin market. Couple this with a less invasive, easy to use, patient friendly delivery system, and we believe you have a product that may revolutionalise insulin treatment for patients and treating physicians in the future.' 

'This transaction highlights our ability to execute collaboration deals with very real commercial potential. The needle-free delivery will open up a wide range of therapeutic options for our candidates and would provide further validation of the possible wide application of Lipoxen's proprietary PolyXen molecules. This is a very exciting time for Lipoxen, and its technologies, and I am confident this collaboration will produce additional value for shareholders.' 

Dr Charles Potter, CEO of Glide Pharma, said: 

'We are very pleased to be collaborating with Lipoxen on a long-acting insulin product. With an estimated 170 million people worldwide suffering from diabetes this product could make a real impact on the management of diabetes in the future, particularly in type 2 diabetes.' 

- ENDS -

Enquiries - Lipoxen PLC

Lipoxen PLC

M. Scott Maguire, Chief Executive Officer

+44 (0)20 7691 3583 

Glide Pharma

+44 (0) 8700 853 700

Charles Potter, CEO

Teathers (nominated adviser)

Claes Spång 

+44 (0)20 7426 9000

Citigate Dewe Rogerson

+44 (0)20 7638 9571

David Dible / Heather Keohane

Notes to Editors on Lipoxen

Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines and oncology drugs based on its proprietary delivery platforms. Lipoxen's PolyXen delivery technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins naturally Lipoxen currently has two products in clinical development using PolyXen, SuliXen, a long acting insulin and ErepoXen a long-acting erythropoietin (EPO). Phase I results with these novel products have shown that they have potential to deliver important dosing advantages to product currently on the market. Both SuliXen and ErepoXen are addressing multi billion dollar markets. Further products under development include improved formulations of important biologicals such as G-CSF, and Interferon-alpha. 

Lipoxen has a second naturally-derived proprietary delivery technology, ImuXen[R] and a related liposomal technology for enhancing the efficacy and safety of various vaccines including multivalent Hepatitis B-E and pneumococcal vaccines . The Company's proprietary delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license agreements in place with Baxter International and Schering Plough . Lipoxen has received funding from the International AIDS Vaccine Initiative (IAVI) to assess the potential of its ImuXen technology to develop an improved HIV vaccine. The Company is also working in collaboration on improved vaccine formulations that could be suitable for refrigeration free distribution, which would enable vaccines to be much more widely distributed to people in the developing world.

Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006..

This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words 'targets', 'believes', 'estimates', 'expects', 'aims', 'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Among the important factors that could cause the Company's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to The Company's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.


Notes to Editors on Glide Pharma 

Glide Pharma is a specialty pharma company focused on easy, safe and convenient solid dose injection of therapeutics and vaccines. Using its proprietary Glide SDI[TM] (Solid Dose Injector) system, Glide Pharma is building a pipeline of in-house and partnered products covering small molecules, peptides, proteins and vaccines. Glide Pharma is currently engaged in six collaborations with pharmaceutical partners.

The Glide SDI is an innovative needle-free drug delivery system that allows the injection of drugs, vaccines and other pharmaceutical ingredients in a solid dosage form.  The drug is formulated as a tiny pointed rod of pharmaceutical material that is pushed through the skin into the underlying tissue where it dissolves releasing the drug into the patient's bloodstream.  The Glide SDI comprises a reusable, spring powered actuator and a pre-filled, disposable drug cassette. The system is very easy to use making it ideal for the self administration of drugs in the home environment. In the clinic, volunteers overwhelmingly stated that they preferred an injection with the Glide SDI to an injection with a standard needle and syringe.  Storing drugs in a solid dosage form typically makes them more stable and therefore refrigeration may not be essential, as is often the case with liquid formulations.  The solid dosage form also enables immediate or controlled release of the drug into the blood stream, thus optimising the drug release profile or reducing the need for multiple injections.

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t